Trial
NCT02355938
Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Baylor College of Medicine
Collaborators
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Condition
Clostridium Difficile
Intervention
Fidaxomicin 200 mg
Why stopped
Lost funding due to low enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-10-13